Ip Share Discussion Threads

[anley] 19/11/2013 17:08

and there were several good buy transactions today - over 100,000 - which is a sign that something else apart from the Graphene listing tomorrow.

[canalet3] 19/11/2013 11:03

Oversubscribed X 2 £11 mill. raised @ 155 wonder if it is coincidence that the price is so close to IP ?

[anley] 18/11/2013 14:29

Graphene to start dealings on 20th and been given a good slug of funds from IPO so it will be interesting to see what the brokers can do on the first day of dealings and the news flow from the company over the next few months.

[anley] 13/11/2013 14:43

Thanks for that.........

[canalet3] 13/11/2013 08:43

London Stock Exchange App. Graphene due to commence trade on 19 Nov.

[broadwood] 08/11/2013 14:51

Going well again. Hopefully won't lose the gains in the auction after the bell.
It mostly did yesterday.

[canalet3] 08/11/2013 14:09

Anybody know when Applied Graphene are due to list ??

[anley] 07/11/2013 10:14

I think it is trying to break out.......

[skinwalker] 05/11/2013 22:46

I'm hopeful that this will soon break out of the recent trading range. Oxford nanopore is crucially important, and there is hopeful news on this front. As long as the gene sequencer impresses, there is scope for a share price of £2 or more. I took some profit at 143p last year but intend to continue to hold for now.

[broadwood] 05/11/2013 16:11

Continuing delayed reaction to good results.

[stats11] 01/11/2013 12:40

Looking good, this could be a real flyer some day!

[broadwood] 01/11/2013 10:34

IP Group said it has made "significant progress" since its half year results as it reported a sharp rise in the value of its investments.

The FTSE 250 group said the fair value of its portfolio had jumped by £52.7m to £258.2m in the four months to October 30th.

The rise was driven by the increase in the share prices of some of the listed companies it has invested in and the £33.3m fair value gain it made on the fundraising last month by Oxford University spin-out Oxford Nanopore in which IP Group has a near 20% stake.

The intellectual property commercialisation company said it had provided incubation, seed and development capital totalling £14.2m to 18 portfolio companies in the last four months including £5m into Cambridge Innovation Capital. Its portfolio now comprises of holdings in 72 companies.

At the end of October it had £23m of cash and its portfolio had net assets of £312m representing 83p a share.

[anley] 30/10/2013 11:35

If they get the Applied Graphene off to a good start then IPO should go as well and look for 170p or more.........that is what the chart combined with news is telling me.

[anley] 29/10/2013 14:57

Welcome to the BB........

[canalet3] 29/10/2013 12:29

Hi new here , asked my broker about Applied graphene ipo and was told discretionary investors only (big money ? ) anyway I thought the best way for a toe in the door was here with IPO, as it looks like AG is going to be well worthwhile and these should profit from their association with them .Any comment ?

[anley] 25/10/2013 13:56

There is some solid buying going on so PEAEFF I hope you did not do the wrong deal!!

I live in Cambridge and the talk is positive.

[peaeff] 24/10/2013 13:17

The trading of these shares is totally eratic and the spreads confusing. I took the opportunity yeaterday to sell, at a small profit, having been in for almost 18 months. I will await developments and may buy back in on any significant fall.

[anley] 24/10/2013 12:26

What an interesting company and one chartist said there is a 10% raise to come in the short term. We will see.........

[peaeff] 23/10/2013 12:34

At last something is happening that will have impact on share price

[fireball xl5] 04/7/2013 16:36

Thats more like it!

[fireball xl5] 13/6/2013 11:34

U.S., British gene sequencing firms split

Melissa Sue Gerrits, Associated Press

Illumina's Sharon Bachman (second from right) trains researchers on the San Diego firm's new tool for genetic sequencing at Avera in Sioux Falls, S.D.
Andrea Gerlin

June 12, 2013

Oxford Nanopore Technologies, the British company racing to develop a portable gene sequencer, and U.S. competitor Illumina will end their partnership in 2016, according to Oxford Nanopore's annual report.

The companies agreed in April to resolve an arbitration demand that Illumina filed in New York state, settling a dispute that arose in 2011, according to the documents posted this week on the website of Companies House in London.


They will also amend an agreement that gave Illumina the right to sell any products that its closely held rival developed using an approach called exonuclease sequencing.

Illumina, which owns 14.7 percent of Oxford Nanopore, also had the right to negotiate a commercialization agreement for products using a strand-sequencing approach if the company sought another partner and an option to complete a transaction for those products on the same terms and conditions as any other suitor.

The rights and the option will cease to exist by Dec. 31, 2016, according to the documents.

"It's incrementally good news" for Oxford Nanopore, said Charles Weston, an analyst at Numis Securities in London. "It adds clarity and it limits the relationship as well. The fact that they are progressing on the strand side and the rights on the strand side are much clearer, that seems a good thing."

Tiny hole

The MinION and GridION systems that Oxford Nanopore is developing use a novel technique known as strand sequencing, in which an entire string of DNA is guided by an enzyme and passes intact through a tiny hole in a cell membrane one-billionth of a meter wide, like a child sucking spaghetti through his mouth.

"Oxford Nanopore has no current intention to commercialize its strand-sequencing technology through a relationship with an entity that is not an affiliate of Oxford Nanopore nor to sell or exclusively license to a third party all of its assets related to strand sequencing technology," it said in the documents.

The company declined to comment further, spokeswoman Zoe McDougall said.

Illumina, located in San Diego, invested $19 million in Oxford Nanopore in January 2009, according to the documents.

Other shareholders include IP Group, which owns about 20 percent, hedge-fund manager Lansdowne Partners and Invesco Perpetual, a British group of mutual funds.

Illumina has had a partnership with Oxford Nanopore since 2009 for products using exonuclease sequencing, in which the DNA building blocks are separated by an enzyme and pass individually through a nanopore.

The companies agreed that Oxford Nanopore isn't obligated to make further efforts to develop such sequencing.

Shares of IP Group rose 0.5 percent to 138.70 pence at 2:02 p.m. in London after gaining as much as 2.8 percent. Weston recommends holding the stock.

Cheaper instruments

Illumina and Life Technologies of Carlsbad (San Diego County) are in a race with Oxford Nanopore to develop faster and cheaper instruments for analyzing sequences of genes.

Oxford Nanopore Chief Executive Officer Gordon Sanghera said more than a year ago that the company planned to begin selling its devices by the end of last year. Oxford Nanopore has since faced technical delays as it has had to redesign components in a custom sensor that weren't performing satisfactorily.

Andrea Gerlin is a Bloomberg writer. E-mail: [e-mail]

hxxp://www.sfchronicle.com/technology/article/U-S-British-gene-sequencing-firms-split-4595066.php

[fireball xl5] 24/5/2013 08:48

Time to resume the ascent.

[the crypt] 22/5/2013 11:25

Get out - get munching on yer cheese